4868 RUE LEVY, SUITE 220, SAINT-LAURENT, A8
Amended material disclosure
Reports Second Quarter 2026 Financial Results and Provides Business Update
2026 Annual Meeting Results - enGene Therapeutics Inc. Shareholder Vote
Annual Report to Security Holders
Investor Presentation
Announces Name Change to Therapeutics Inc.
enGene Holdings Inc. Enters Sales Agreement with Leerink Partners
Financial Results, Press Release
Q1
Amended Annual Report
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence